Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082515 | 0.89 | SMN1; SMN2 (0.44) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1025492 | 0.86 | SCD (0.57) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1022885 | 0.84 | SCD (0.48) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1074629 | 0.84 | SCD (0.45) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL4128215 | 0.82 | SMN1; SMN2 (0.41) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1074645 | 0.80 | FLT1 (0.36) | SCDSMN1; SMN2LMNAMAPK1 | |
| SCHEMBL1074313 | 0.80 | SCD (0.41) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1074765 | 0.79 | SCD (0.45) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1021354 | 0.79 | SMN1; SMN2 (0.42) | SCDSMN1; SMN2LMNAHTTUBE2N | |
| SCHEMBL1071820 | 0.79 | SMN1; SMN2 (0.43) | SCDSMN1; SMN2LMNAHTTUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274308-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-19 | — | — | EP | claimed |
| WO-2009124259-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | WO | claimed |
| US-20090253704-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. | 2009-10-08 | — | — | US | claimed |
| EP-2274308-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009124259-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL COA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090253704-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253704-A1 | PYRROLOTRIAZINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, ECHS1 | SCD 1/4885SMN1; SMN2 4467/4885LMNA 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.